Promoted Companies
SORT BY:
ArQule Inc. (ARQL)
| Total paid for Promotions this month: | $0 | ||
| E-mails this Month: | 4 | ||
| Estimated Volume Generated: | $0 | ||
| Research Report on ARQL: | Click to see | ||
| * The information presented is based on information for Jan , 2014 | |||
Biotech Alert: Positive Clinical Trials Update Could Attract Radar... Jan 17, 2014 03:05
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
ArQule Inc. (ARQL)
Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous
...read more
| Promoter: | Crweselect.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| ARQL | Unknown compensation | UNKNOWN |
| Max Profit: 4.66 % | Gain at close: -9.68 % |
Biotech Alert: Positive Clinical Trials Update Could Attract Radar... Jan 17, 2014 02:37
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
ArQule Inc. (ARQL)
Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous
...read more
| Promoter: | pennyomega.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| ARQL | Unknown compensation | UNKNOWN |
| Max Profit: 4.66 % | Gain at close: -9.68 % |
Biotech Alert: Positive Clinical Trials Update Could Attract Radar... Jan 17, 2014 02:11
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
ArQule Inc. (ARQL)
Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous
...read more
| Promoter: | stockbling.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| ARQL | Unknown compensation | UNKNOWN |
| Max Profit: 4.66 % | Gain at close: -9.68 % |
Biotech Alert: Positive Clinical Trials Update Could Attract Radar... Jan 17, 2014 02:09
Biotech Alert: Positive Clinical Trials Update Could Attract Radar Signals
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
ArQule Inc. (ARQL)
Keep a close eye on ARQL. The company provided positive clinical updates on the ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma (liver cancer), and on the completed amended Phase 3 ATTENTION trial in non-squamous
...read more
| Promoter: | penny to buck | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| ARQL | Unknown compensation | UNKNOWN |
| Max Profit: 4.66 % | Gain at close: -9.68 % |